284 related articles for article (PubMed ID: 8200983)
1. In situ glucose uptake and glucokinase activity of pancreatic islets in diabetic and obese rodents.
Liang Y; Bonner-Weir S; Wu YJ; Berdanier CD; Berner DK; Efrat S; Matschinsky FM
J Clin Invest; 1994 Jun; 93(6):2473-81. PubMed ID: 8200983
[TBL] [Abstract][Full Text] [Related]
2. Modulation by glucose of insulin secretion and glucose phosphorylating activity in cultured pancreatic islets from obese (fa/fa) Zucker rats.
Chan CB; Lowe JM; Debertin WJ
Int J Obes Relat Metab Disord; 1996 Feb; 20(2):175-84. PubMed ID: 8646255
[TBL] [Abstract][Full Text] [Related]
3. High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction.
Kooptiwut S; Kebede M; Zraika S; Visinoni S; Aston-Mourney K; Favaloro J; Tikellis C; Thomas MC; Forbes JM; Cooper ME; Dunlop M; Proietto J; Andrikopoulos S
J Mol Endocrinol; 2005 Aug; 35(1):39-48. PubMed ID: 16087720
[TBL] [Abstract][Full Text] [Related]
4. Changes in pancreatic islet glucokinase and hexokinase activities with increasing age, obesity, and the onset of diabetes.
Cockburn BN; Ostrega DM; Sturis J; Kubstrup C; Polonsky KS; Bell GI
Diabetes; 1997 Sep; 46(9):1434-9. PubMed ID: 9287043
[TBL] [Abstract][Full Text] [Related]
5. Effect of adrenalectomy on the development of a pancreatic islet lesion in fa/fa rats.
Kibenge MT; Chan CB
Diabetologia; 1996 Feb; 39(2):190-8. PubMed ID: 8635671
[TBL] [Abstract][Full Text] [Related]
6. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
Tsumura Y; Tsushima Y; Tamura A; Hasebe M; Kanou M; Kato H; Kobayashi T
PLoS One; 2017; 12(2):e0172252. PubMed ID: 28207836
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice.
Liang Y; Lubkin M; Sheng H; Scislowski PW; Cincotta AH
Biochim Biophys Acta; 1998 Oct; 1405(1-3):1-13. PubMed ID: 9784590
[TBL] [Abstract][Full Text] [Related]
8. Genetically obese rats with (SHR/N-cp) and without diabetes (LA/N-cp) share abnormal islet responses to glucose.
Timmers KI; Voyles NR; Recant L
Metabolism; 1992 Oct; 41(10):1125-33. PubMed ID: 1406299
[TBL] [Abstract][Full Text] [Related]
9. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.
Doliba NM; Qin W; Najafi H; Liu C; Buettger CW; Sotiris J; Collins HW; Li C; Stanley CA; Wilson DF; Grimsby J; Sarabu R; Naji A; Matschinsky FM
Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E87-E102. PubMed ID: 21952036
[TBL] [Abstract][Full Text] [Related]
10. Glucokinase, hexokinase, glucose transporter 2, and glucose metabolism in islets during pregnancy and prolactin-treated islets in vitro: mechanisms for long term up-regulation of islets.
Weinhaus AJ; Stout LE; Sorenson RL
Endocrinology; 1996 May; 137(5):1640-9. PubMed ID: 8612496
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glucose-stimulated insulin release by pseudo-alpha-DL-glucose as a glucokinase inhibitor.
Miwa I; Hara H; Okuda J; Suami T; Ogawa S
Biochem Int; 1985 Dec; 11(6):809-16. PubMed ID: 3911958
[TBL] [Abstract][Full Text] [Related]
12. Reducing Glucokinase Activity Restores Endogenous Pulsatility and Enhances Insulin Secretion in Islets From db/db Mice.
Jahan I; Corbin KL; Bogart AM; Whitticar NB; Waters CD; Schildmeyer C; Vann NW; West HL; Law NC; Wiseman JS; Nunemaker CS
Endocrinology; 2018 Nov; 159(11):3747-3760. PubMed ID: 30239634
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatment with sympatholytic dopamine agonists improves aberrant beta-cell hyperplasia and GLUT2, glucokinase, and insulin immunoreactive levels in ob/ob mice.
Jetton TL; Liang Y; Cincotta AH
Metabolism; 2001 Nov; 50(11):1377-84. PubMed ID: 11699060
[TBL] [Abstract][Full Text] [Related]
14. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator.
Johnson D; Shepherd RM; Gill D; Gorman T; Smith DM; Dunne MJ
Diabetes; 2007 Jun; 56(6):1694-702. PubMed ID: 17360975
[TBL] [Abstract][Full Text] [Related]
15. Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research.
Polonsky KS
Diabetes; 1995 Jun; 44(6):705-17. PubMed ID: 7789637
[TBL] [Abstract][Full Text] [Related]
16. Role of Islet Glucokinase, Glucose Metabolism, and Insulin Pathway in the Enhancing Effect of Islet Neogenesis-Associated Protein on Glucose-Induced Insulin Secretion.
Maiztegui B; Román CL; Barbosa-Sampaio HC; Boschero AC; Gagliardino JJ
Pancreas; 2015 Aug; 44(6):959-66. PubMed ID: 25906449
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity.
Radu RG; Fujimoto S; Mukai E; Takehiro M; Shimono D; Nabe K; Shimodahira M; Kominato R; Aramaki Y; Nishi Y; Funakoshi S; Yamada Y; Seino Y
Am J Physiol Endocrinol Metab; 2005 Feb; 288(2):E365-71. PubMed ID: 15479952
[TBL] [Abstract][Full Text] [Related]
18. Anomeric dissociation between glucokinase activity and glycolysis in pancreatic islets.
Sener A; Giroix MH; Leclercq-Meyer V; Marchand J; Malaisse WJ
Biochem Int; 1985 Jul; 11(1):77-84. PubMed ID: 3899118
[TBL] [Abstract][Full Text] [Related]
19. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
Axen KV; Li X; Sclafani A
Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
[TBL] [Abstract][Full Text] [Related]
20. New perspectives on pancreatic islet glucokinase.
Meglasson MD; Matschinsky FM
Am J Physiol; 1984 Jan; 246(1 Pt 1):E1-13. PubMed ID: 6364828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
